N-[1(S)-(cyclohexylmethyl)-2(R),3(S)-dihydroxy-5-methylhexyl]-5(S)-benzyloxy-4(S)-[(tert-butyldimethylsilyl)oxy]-2(R)-(cyclopropylmethyl)-6-phenylhexanamide | 155295-61-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[1(S)-(cyclohexylmethyl)-2(R),3(S)-dihydroxy-5-methylhexyl]-5(S)-benzyloxy-4(S)-[(tert-butyldimethylsilyl)oxy]-2(R)-(cyclopropylmethyl)-6-phenylhexanamide
• 英文别名: (2R,4S,5S)-4-[tert-butyl(dimethyl)silyl]oxy-N-[(2S,3R,4S)-1-cyclohexyl-3,4-dihydroxy-6-methylheptan-2-yl]-2-(cyclopropylmethyl)-6-phenyl-5-phenylmethoxyhexanamide
• CAS: 155295-61-7
• 化学式: C₄₃H₆₉NO₅Si
• 分子量: 708.11
• InChiKey: BYXWKAUKLZNZPD-BSSJTXDNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  9.23
• 重原子数：
  50
• 可旋转键数：
  21
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  88
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-[1(S)-(cyclohexylmethyl)-2(R),3(S)-dihydroxy-5-methylhexyl]-5(S)-benzyloxy-4(S)-[(tert-butyldimethylsilyl)oxy]-2(R)-(cyclopropylmethyl)-6-phenylhexanamide 在 四丁基氟化铵 作用下， 以 四氢呋喃 为溶剂， 反应 18.2h， 以87%的产率得到N-[1(S)-(cyclohexylmethyl)-2(R),3(S)-dihydroxy-5-methylhexyl]-2(R)-(cyclopropylmethyl)-5(S)-benzyloxy-4(S)-hydroxy-6-phenylhexanamide
  参考文献：
  名称：

  Novel small renin inhibitors containing 4,5- or 3,5-dihydroxy-2-substituted-6-phenylhexanamide replacements at the P2P3 sites

  摘要：

  Renin inhibitors containing a 4,5- or a 3,5-dihydroxy-2-substituted-6-phenylhexanamide fragment at the P-2- P-3 Sites have been prepared and evaluated. The four possible diastereomeric diols of the two series of inhibitors were synthesized to determine the optimal configuration of the carbinol centers for these replacements. The most potent inhibitors of each series, 1a and 2c have a molecular weight of only 503 and IC50 values of 23 and 20 nM in a human plasma renin assay at pH 6.0. Their very low aqueous solubility limited their further evaluation. The efficacy of these P-2-P-3 replacements is a result of their ability to maintain the important hydrogen-bonds with the enzyme. Due to conformational differences with the dipeptide, adjustment at the P-2 Side chain was required. These 4,5- and 3,5-dihydroxyhexanamide segments could be seen as novel N-terminal dipeptide replacements. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(98)80011-4
• 作为产物：
  描述：

  L-(-)-3-苯基乳酸 在 palladium diacetate sodium hydroxide 、 lithium aluminium tetrahydride 、 正丁基锂 、 jones' reagent 、 草酰氯 、 sodium hydride 、 碳酸氢钠 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 1-羟基苯并三唑 、 臭氧 、 二甲基亚砜 、 三乙胺 、 N,N-二异丙基乙胺 、 柠檬酸 作用下， 以 四氢呋喃 、 甲醇 、 乙醚 、 正己烷 、 二氯甲烷 、 水 、 乙酸乙酯 、 丙酮 为溶剂， 反应 259.5h， 生成 N-[1(S)-(cyclohexylmethyl)-2(R),3(S)-dihydroxy-5-methylhexyl]-5(S)-benzyloxy-4(S)-[(tert-butyldimethylsilyl)oxy]-2(R)-(cyclopropylmethyl)-6-phenylhexanamide
  参考文献：
  名称：

  Novel small renin inhibitors containing 4,5- or 3,5-dihydroxy-2-substituted-6-phenylhexanamide replacements at the P2P3 sites

  摘要：

  Renin inhibitors containing a 4,5- or a 3,5-dihydroxy-2-substituted-6-phenylhexanamide fragment at the P-2- P-3 Sites have been prepared and evaluated. The four possible diastereomeric diols of the two series of inhibitors were synthesized to determine the optimal configuration of the carbinol centers for these replacements. The most potent inhibitors of each series, 1a and 2c have a molecular weight of only 503 and IC50 values of 23 and 20 nM in a human plasma renin assay at pH 6.0. Their very low aqueous solubility limited their further evaluation. The efficacy of these P-2-P-3 replacements is a result of their ability to maintain the important hydrogen-bonds with the enzyme. Due to conformational differences with the dipeptide, adjustment at the P-2 Side chain was required. These 4,5- and 3,5-dihydroxyhexanamide segments could be seen as novel N-terminal dipeptide replacements. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(98)80011-4